Declining Trends of Pneumococcal Meningitis in Gambian Children After the Introduction of Pneumococcal Conjugate Vaccines.
Acute Disease
/ epidemiology
Child, Preschool
Female
Gambia
/ epidemiology
Haemophilus influenzae type b
/ classification
Hospitalization
/ statistics & numerical data
Humans
Infant
Infant, Newborn
Male
Meningitis, Meningococcal
/ epidemiology
Meningitis, Pneumococcal
/ cerebrospinal fluid
Neisseria meningitidis
/ classification
Pneumococcal Vaccines
/ administration & dosage
Sentinel Surveillance
Serogroup
Streptococcus pneumoniae
/ classification
Vaccines, Conjugate
/ administration & dosage
Whole Genome Sequencing
Haemophilus influenzae
Neisseria meningitidis
Streptococcus pneumoniae
pediatric bacterial meningitis
pneumococcal conjugate vaccines
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
05 09 2019
05 09 2019
Historique:
entrez:
11
9
2019
pubmed:
11
9
2019
medline:
29
9
2020
Statut:
ppublish
Résumé
Acute bacterial meningitis remains a major cause of childhood mortality in sub-Saharan Africa. We document findings from hospital-based sentinel surveillance of bacterial meningitis among children <5 years of age in The Gambia, from 2010 to 2016. Cerebrospinal fluid (CSF) was collected from children admitted to the Edward Francis Small Teaching Hospital with suspected meningitis. Identification of Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus influenzae was performed by microbiological culture and/or polymerase chain reaction where possible. Whole genome sequencing was performed on pneumococcal isolates. A total of 438 children were admitted with suspected meningitis during the surveillance period. The median age of the patients was 13 (interquartile range, 3-30) months. Bacterial meningitis was confirmed in 21.4% (69/323) of all CSF samples analyzed. Pneumococcus, meningococcus, and H. influenzae accounted for 52.2%, 31.9%, and 16.0% of confirmed cases, respectively. There was a significant reduction of pneumococcal conjugate vaccine (PCV) serotypes, from 44.4% in 2011 to 0.0% in 2014, 5 years after PCV implementation. The majority of serotyped meningococcus and H. influenzae belonged to meningococcus serogroup W (45.5%) and H. influenzae type b (54.5%), respectively. Meningitis pathogens were more frequently isolated during the dry dusty season of the year. Reduced susceptibility to tetracycline, trimethoprim-sulfamethoxazole, and chloramphenicol was observed. No resistance to penicillin was found. The proportion of meningitis cases due to pneumococcus declined in the post-PCV era. However, the persistence of vaccine-preventable meningitis in children aged <5 years is a major concern and demonstrates the need for sustained high-quality surveillance.
Sections du résumé
BACKGROUND
Acute bacterial meningitis remains a major cause of childhood mortality in sub-Saharan Africa. We document findings from hospital-based sentinel surveillance of bacterial meningitis among children <5 years of age in The Gambia, from 2010 to 2016.
METHODS
Cerebrospinal fluid (CSF) was collected from children admitted to the Edward Francis Small Teaching Hospital with suspected meningitis. Identification of Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus influenzae was performed by microbiological culture and/or polymerase chain reaction where possible. Whole genome sequencing was performed on pneumococcal isolates.
RESULTS
A total of 438 children were admitted with suspected meningitis during the surveillance period. The median age of the patients was 13 (interquartile range, 3-30) months. Bacterial meningitis was confirmed in 21.4% (69/323) of all CSF samples analyzed. Pneumococcus, meningococcus, and H. influenzae accounted for 52.2%, 31.9%, and 16.0% of confirmed cases, respectively. There was a significant reduction of pneumococcal conjugate vaccine (PCV) serotypes, from 44.4% in 2011 to 0.0% in 2014, 5 years after PCV implementation. The majority of serotyped meningococcus and H. influenzae belonged to meningococcus serogroup W (45.5%) and H. influenzae type b (54.5%), respectively. Meningitis pathogens were more frequently isolated during the dry dusty season of the year. Reduced susceptibility to tetracycline, trimethoprim-sulfamethoxazole, and chloramphenicol was observed. No resistance to penicillin was found.
CONCLUSIONS
The proportion of meningitis cases due to pneumococcus declined in the post-PCV era. However, the persistence of vaccine-preventable meningitis in children aged <5 years is a major concern and demonstrates the need for sustained high-quality surveillance.
Identifiants
pubmed: 31505634
pii: 5561335
doi: 10.1093/cid/ciz505
pmc: PMC6761313
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S126-S132Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Acta Trop. 2017 May;169:51-56
pubmed: 28122199
Nucleic Acids Res. 2016 Jul 8;44(W1):W242-5
pubmed: 27095192
Pediatr Infect Dis J. 2004 Jan;23(1):73-4
pubmed: 14743052
Clin Infect Dis. 2008 Mar 15;46(6):807-14
pubmed: 18279039
J Pediatr. 2013 Jul;163(1 Suppl):S4-7
pubmed: 23773593
Microb Genom. 2015 Aug 11;1(2):e000027
pubmed: 28348812
MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1159-62
pubmed: 25503919
PLoS One. 2016 Feb 01;11(2):e0147765
pubmed: 26829233
PLoS Med. 2011 Oct;8(10):e1001107
pubmed: 22028630
J Infect Dis. 2004 Dec 1;190(11):2031-8
pubmed: 15529269
Trop Med Int Health. 1998 Sep;3(9):742-6
pubmed: 9754670
mSphere. 2016 Nov 16;1(6):
pubmed: 27904879
BMC Infect Dis. 2016 Oct 18;16(1):575
pubmed: 27756235
J Clin Microbiol. 2013 Feb;51(2):647-52
pubmed: 23224094
Lancet Infect Dis. 2016 Jun;16(6):703-711
pubmed: 26897105
Clin Infect Dis. 2005 Jan 1;40(1):17-25
pubmed: 15614687
PLoS One. 2016 Jul 5;11(7):e0158938
pubmed: 27379429
Bioinformatics. 2006 Nov 1;22(21):2688-90
pubmed: 16928733
Emerg Infect Dis. 2013;19(9):1507-10
pubmed: 23965435
Afr Health. 1997 Nov;20(1):13, 15
pubmed: 12348371
Hum Vaccin Immunother. 2016;12(2):314-25
pubmed: 26317537
Am J Clin Pathol. 1984 May;81(5):651-4
pubmed: 6720631
Lancet. 2005 Jul 9-15;366(9480):144-50
pubmed: 16005337
Lancet Infect Dis. 2017 Aug;17(8):867-872
pubmed: 28545721
Cost Eff Resour Alloc. 2016 Feb 17;14:4
pubmed: 26893592
Vaccine. 2009 Jun 24;27 Suppl 2:B13-9
pubmed: 19477559
N Engl J Med. 2014 Nov 13;371(20):1889-99
pubmed: 25386897